Experts from the American Diabetes Association (AD), of the European Association for the Study of Diabetes (EASD) and the Spanish Diabetes Society (SED) have analyzed the latest newsAround diabetes during the IV edition of the scientific meeting 'Best of Ada Spain'.
With these days it is intended to contribute to examining how to improve the effectiveness of treatments and, with it, the care and quality of life of patients with this chronic disease.In this way, more than 200 diabetes specialists throughout Spain, attended this event to learn about the most recent studies and the conclusions of the 75th edition of the ADA, which took place on June 5 in Boston (United States).
"This edition has served as a meeting point for professionals and patients involved in the fight against the mortal consequences of diabetes, with the aim of facilitating day to day and improving the quality of life of those affected by this pathology," hecommented on the medical and scientific director of the ADA, Dr. Ratner.
Among the topics discussed, the presentation of the results of the most recent clinical trials, of cardiovascular results in this pathology has highlighted.In addition, the update of the guides in diabetes ('Tandards of Medical Care 2015', neurodegeneration as an early event of diabetic retinopathy, the long -term consequences of youth obesity, the impact of hypoglycemia in clinical practice have been analyzed, the relationship of microbiome and metabolism, among others.
The latest research has revealed cardiovascular safety of sitegliptin treatment, added to usual therapy, in patients with type II diabetes and high cardiovascular risk, demonstrating that it does not increase the risk of cardiovascular events or hospitalization due to heart failure.
On the other hand, in this edition, sponsored by Ferrer, in addition to the professor at the University of Georgetown Medicine, Robert Ratner, experts such as Richard Pratley have participated, of the Orlando Diabetes Institute;Simon Heller, Clinical Diabetes Professor at the University of Sheffield;and Rafael Simó, of the Research Institute of the Vall D*Hebron University Hospital, among others.